Sabag Mark 4

What Happened

• Mark Sabag, Executive Vice President, International Markets Commercial at Teva Pharmaceutical Industries (TEVA), had restricted share units (RSUs) vest and convert into ordinary shares and also received a new RSU award on March 4, 2026. Specifically, 33,512 RSUs and 18,601 RSUs vested and were converted (total 52,113 shares), and he was granted 30,385 new RSUs. The reported per-share price is $0.00, indicating these were awards/conversions rather than cash purchases or open-market sales.

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (appears timely).
• Converted/Exercised (M): 33,512 and 18,601 RSUs converted to shares (total 52,113); reported disposal price $0.00 (conversion, not a sale).
• Grant/Award (A): 30,385 RSUs granted on March 4, 2026 at $0.00.
• Footnotes: F1 notes ordinary shares may be represented by American Depositary Shares (ADS). F3–F5 detail vesting schedules: the converted RSUs were from earlier grants (2022 and 2024) that vested on March 4, 2026; the new 2026 grant vests in installments (2027–2030).
• Shares owned after the transactions are not specified in the supplied filing details.

Context

• These entries reflect routine equity compensation activity (vesting/conversion of RSUs and a new RSU grant), not open-market buying or selling. The $0.00 amounts indicate conversion/award mechanics rather than cash transactions; no immediate sale of shares is reported here. Such grants and vesting are standard for executives and do not by themselves indicate a buy or sell signal.